HDAC6 and Charcot-Marie-Tooth disease type 2: In CMT2, histone deacetylase 6 (HDAC6) has also been signaled as a potential therapeutic target for the amelioration of the neurodegenerative phenotype, reversing motor and sensory deficits induced by Hsp27 activation [49].